Breaks Categories: News

TuesdayAug 16, 2022 11:46 am

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Results of Annual Meeting of Shareholders

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM)”, today announced voting results for each of the matters presented at the company’s annual shareholders’ meeting. There were 71 shareholders represented in person or by proxy, holding 47,019,721 common shares, representing 28.3% of Cybin’s total issued and outstanding common shares as at the record date for the meeting held on Aug. 15, 2022. The announcement details voting results for each matter presented, including the appointment of Zeifmans LLP as auditor and election of directors. Each of the nominees listed in Cybin’s July 13 management information…

Continue Reading

MondayAug 15, 2022 12:27 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2022 Financial Results, Corporate Update

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today reported its financial results for the quarter ended June 30, 2022, and provided a clinical update of its anti-cancer drug candidates currently in development. “Within the past six months alone, we have executed on a number of clinical and operational advancements including expanding our global presence with clinical approvals in Spain, France and Switzerland to drive patient enrollment forward, as well as expanding eligibility for patients to participate in our…

Continue Reading

ThursdayAug 11, 2022 11:50 am

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Shares Favre Interview

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products including a novel compound for the treatment of concussion, is sharing an interview by NFL Hall of Famer Brett Favre. During the interview, hosted by Bubba, the Love Sponge(R), Favre talks about the many concussions he received while playing football. Earlier this week, Favre did another interview with ODYY head of drug development Dr. Jacob VanLandingham, in which he also talked about concussions. During the interview with Bubba, the Love Sponge, Favre explained that when he left the NFL years ago, he…

Continue Reading

WednesdayAug 10, 2022 12:28 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Positive Results from MAD Arm of Phase I Trial

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, today announced the completion and safety findings from Cohort I of its Multi-Day Ascending Dosing (“MAD”) arm for its phase I clinical trial. The trial is administering PRV-002, Odyssey’s novel drug to treat concussion, to healthy human subjects. According to the update, MAD Cohort I subjects were dosed for five consecutive days, with the drug, PRV-002, safe and well tolerated. “As the head of drug development for the PRV-002 concussion treatment, I was very happy to see these positive safety results when dosing for multiple days,” said…

Continue Reading

TuesdayAug 09, 2022 12:50 pm

BioMedNewsBreaks – Odyssey Health Inc.’s (ODYY) Dr. Jacob VanLandingham, Brett Favre Featured in ‘Get Authentic’ Podcast

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, was featured in a recent episode of Get Authentic with Marques Ogden, a podcast series delivering honest, unfiltered and real-time stories from legendary athletes and industry leaders. NFL Hall of Famer Brett Favre and Dr. Jacob VanLandingham, head of drug development for Odyssey Health, joined the program, where Dr. VanLandingham discussed the unique selling proposition of Odyssey’s development pipeline. Favre also discussed the last days of his NFL career and his focus as a member of Odyssey’s sports advisory board. “My last play [in the NFL] was…

Continue Reading

TuesdayAug 09, 2022 12:37 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Board Appointment, Changes

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced the appointment of Nicole Lemerond to its board of directors, effective immediately. Lemerond is a financial executive with over 25 years of experience in investment management, private equity, investment banking and leveraged finance. Throughout her career, she has established and led health care groups at leading investment firms and has also worked at several large financial institutions, including Lehman Brothers and The Carlyle Group. Concurrent with Lemerond’s appointment, Adam Cutler has decided to transition off the board of directors. Cutler has served…

Continue Reading

TuesdayAug 09, 2022 11:58 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Unveils Equity Program, Releases Q1 Financial Report

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced an at-the-market equity program allowing the company to issue and sell up to $35 million of common shares. According to the announcement, the shares can be sold “from time to time” through the Neo Exchange, the NYSE American LLC or any other “marketplace” upon which the shares are listed, quoted or traded, at the prevailing market price at the time of sale. The company anticipates using any proceeds from the sales of these shares for growth opportunities and working capital initiatives. In addition, Cybin…

Continue Reading

ThursdayAug 04, 2022 12:07 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Unveils New Corporate Website

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, today announced the launch of its new corporate website. Consistent with the company’s recent name change, the new website was designed to better reflect Odyssey Health’s mission and focus while also improving communication strategies with current and potential shareholders, institutions, and various scientific and financial publications. “The launch of our new website is an important next step in the ongoing evolution of Odyssey and will enable us to provide more transparent communications with our shareholders and other stakeholders,” said Odyssey Health CEO Michael Redmond. “We are excited…

Continue Reading

TuesdayAug 02, 2022 12:20 pm

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Featured in Bell2Bell Podcast

Aditxt (NASDAQ: ADTX) was featured in the Bell2Bell Podcast, a part of IBN’s (InvestorBrandNetwork) sustained effort to provide specialized content distribution via widespread syndication channels. Amro Albanna, co-founder, chairman and CEO of Aditxt, joined the latest episode to provide an overview of the company and discuss its business model. “We are a biotech innovation company, and our focus is on immune diseases. The reality is that immune diseases are caused either by someone having too little immune response or too much immune response,” Albanna said. “When you have too little immune response and you’re dealing with COVID-19, we all understand…

Continue Reading

ThursdayJul 28, 2022 10:58 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO to Participate in Upcoming Canaccord Genuity Growth Conference

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be presenting at the 42nd annual Canaccord Genuity Growth Conference; the four-day event is scheduled for Aug. 8–11, 2022, in Boston. During the conference, Cybin CEO Doug Drysdale will present a fireside chat. Drysdale’s presentation is slated for Thursday, Aug. 11, 2022, at 3:30 p.m. ET. Interested individuals are invited to watch a live webcast of the event or an archived version of the event, available on the company’s investor relations page following the live presentation. To view the live presentation, visit https://ibn.fm/ghBjR To view…

Continue Reading